Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

EN PROSPEKTIV, MULTI-CENTER, ENARM, OBSERVATIONSSTUDIE EFTER MARKNADEN FÖR ATT UTVÄRDERA SÄKERHETEN OCH KLINISKA PRESTANDA HOS ARCHIMEDES BIOLOGISKT NEDBRYTBAR BILIAR- OCH BUKSKREASSTENT (Registry)

1 oktober 2026 uppdaterad av: QualiMed Innovative Medizinprodukte GmbH

Significant experience with biodegradable materials has been reported in the orthopedic literature; in particular; biodegradable stents have been used in the endovascular and urologic epithelium. Stents are typically made from polymeric materials including Polylactic Acid (PLA), Polyglycolide (PGA), Polydioxanone (PDO), Polyethyleneglycol (PEG), Polycaprolactone (PCL), etc., which have been cleared or approved by the FDA and CE-marked as drug carriers, sutures, and bone fixatives. The material is degraded by hydrolysis in, e.g., lactic acid, which is removed from the body by normal metabolic pathways. In the field of gastroenterology, these stents were first introduced in patients with an esophageal stenosis with encouraging results, although esophageal hyperplasia was a frequently encountered complication.

For biliary applications, biodegradable stents have been evaluated in several in-vitro and animal studies that demonstrated that the stents were safe and well tolerated. These stents provided an adequate radial force and resulted in complete stricture resolution within several months. The stents did not show any signs of biliary hyperplasia or integration in the epithelium. Moreover, they seem to have a self-clearing effect on attached biofilm as the outer layer sloughs during the degradation process similarly to the exfoliation of human skin. Also, the stent could be removed from the bile duct, thus offering the possibility of extraction if necessary at various times after implantation.

In 2010, Petryl was the first to use a biodegradable stent in the human bile duct. A stent was successfully placed using percutaneous transhepatic cholangiograpy in two patients with a postsurgical intrahepatic biliary stricture. Transient cholangitis was the only complication encountered and during the two years of follow-up, the bile duct remained patent.

Later, Mauri et al. presented in 2013 and 2016 results of a 107 patient study on a polydioxanone biodegradable biliary stent. The results have been published in the Journal of the European Society of Radiology. The authors concluded that percutaneous placement of a biodegradable biliary stent is a feasible and safe strategy to treat benign biliary strictures refractory to standard bilioplasty, with promising results in the mid-term period.

Prior to this study, the ARCHIMEDES device was assessed in the ARCHIMEDES Investigational study which has completed enrolment with 53 patients included, and the results are not yet published. In this study approximately half the stents were deployed in the bile duct (53%) and half in the pancreatic duct. All 53 patients have either completed, exited, or no longer have the study device. No patient remains in the study with a stent in place during the time of the last patient follow-ups. The study concluded without any device-related SAE. Bilirubin was reduced by 25.6%, which exceeded the >20% clinical success criterion, quality of life score improved from 3.7 to 7.9, procedural success was rated 1.4 (good to excellent), and technical success was achieved in all 53 patients.

Data from the ARCHIMEDES Investigational study was used for CE Mark approval, which was obtained in June 2018.

Studieöversikt

Studietyp

Observationell

Inskrivning (Beräknad)

198

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Helsinki, Finland, 00290
        • Avslutad
        • HUS Helsinki University Hospital
      • Paris, Frankrike, 75015
        • Aktiv, inte rekryterande
        • Hôpital Européen Georges-Pompidou HEGP Service d'Hépato-gastro-entérologie et endoscopies digestives
      • Afula, Israel, 1834111
        • Avslutad
        • Emek Medical Center
      • Forlì, Italien, 47121
        • Avslutad
        • AUSL Romagna Ospedale Morgagni - Pierantoni
      • Pavia, Italien, 27100
        • Aktiv, inte rekryterande
        • Gastroenterology and Digestive Endoscopy Unit Fondazione I.R.C.C.S. Policlinico San Matteo
      • Roma, Italien, 00128
        • Aktiv, inte rekryterande
        • UCBM - Campus Bio-Medico University
    • Milano
      • Rozzano, Milano, Italien, 20089
        • Aktiv, inte rekryterande
        • Endoscopy Unit, Humanitas Research Hospital
      • Singapore, Singapore, 308433
        • Avslutad
        • Tan Tock Seng Hospital Pte Ltd,
      • Ljubljana, Slovenien, 1000
        • Rekrytering
        • University Medical Center Ljubljana
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Dr Samo Plut, MD
      • Salamanca, Spanien, 37007
        • Rekrytering
        • Hospital Universitario de Salamanca
        • Kontakt:
        • Huvudutredare:
          • Dr. Alberto Álvarez Delgado, MD, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients that will respect the inlcusion criteria will be enrolled in the study.

Beskrivning

Inclusion Criteria:

  • Patient eligible for implantation of a pancreatic or billiary stent prior to participate in the study and according to current guidelines
  • Patient has provided a signed and dated informed consent (according to the laws and regualtions of the country in which the observational study is conducted)

Exclusion Criteria:

  • Age < 18 y
  • Inability to understand the purpose of the study or refusal to cooperate
  • Not available for routine follow-up visits
  • Pregnancy
  • Currently participating in a confounding trial before reaching first endpoint.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Patients will treated with ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in routine practice

Participants receiving commercially available ARCHIMEDES Biodegradable Biliary and Pancreatic as part of standard care. Safety outcomes are collected for post-marketing surveillance

Patients will treated with ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in routine clinical practice

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Primary Safety endpoint
Tidsram: From enrollment to the end of treatment, as per the standard of care.

Proportion of subjects experiencing procedure- or device-related complications within 30 days including Post-ERCP pancreatitis, Bleeding, Perforation (biliary/pancreatic/duodenal), Stent misplacement, Stent migration, Biliary occlusion, Cholangitis, Severe pain, All-cause death Within 30 days of the index procedure

From enrollment to the end of treatment, as per the standard of care.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Secondary endpoints are defined as:
Tidsram: Technical and Procedural success on the Procedure day and clinical success as per the Standard of Care

Clinical success: patency rate as defined by the rate of freedom of stent replacements at follow-up time points defined by investigators definition of SOC (standard of care) or until planned bridge surgery (defined as no need of stent replacement).

Technical success: Accurate stent deployment across the target stricture as evaluated by fluoroscopy and endoscopy.

Procedural success will be quantified (using a dedicated score system, Excellence=1, Good=2, Fair=3, Poor=4) by the endoscopist post procedure using the following components:

  • Stent loadability
  • Trackability over Guide Wire
  • Pushibility with push catheter
  • Visualization by fluoroscopy
  • Stent repositiong when required
  • Deployment accuracy
Technical and Procedural success on the Procedure day and clinical success as per the Standard of Care

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 oktober 2020

Primärt slutförande (Beräknad)

30 juni 2027

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

8 januari 2021

Först inskickad som uppfyllde QC-kriterierna

12 januari 2021

Första postat (Faktisk)

13 januari 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • QM-NI-ABS-034

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera